Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Fleurence

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Visualized Experiments : Jove|February 9, 2019
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index EquationMeriem Bahri, Julien Fleurence, Sébastien Faraj, et al.
Journal of Immunology Research|February 4, 2017
Targeting <i>O</i>-Acetyl-GD2 Ganglioside for Cancer ImmunotherapyJulien Fleurence, Sophie Fougeray, Meriem Bahri, et al.
Oncoimmunology|June 5, 2013
Inhibition of tumor angiogenesis by globotriaosylceramide immunotargetingStéphane Birklé, Ariane Desselle, Tanguy Chaumette, et al.
Plos One|November 29, 2012
Anti-Gb3 monoclonal antibody inhibits angiogenesis and tumor developmentAriane Desselle, Tanguy Chaumette, Marie-Hélène Gaugler, et al.
Oncotarget|May 14, 2016
Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 gangliosideJulien Fleurence, Denis Cochonneau, Sophie Fougeray, et al.
Cancer Immunology Research|January 19, 2020
Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular CarcinomaSai Arun Batra, Purva Rathi, Linjie Guo, et al.
International Journal of Cancer|June 27, 2019
Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 gangliosideJulien Fleurence, Meriem Bahri, Sophie Fougeray, et al.
Research Square|April 22, 2024
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancersDavid Steffin, Nisha Ghatwai, Antonino Montalbano, et al.
Nature|November 28, 2024
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancersDavid Steffin, Nisha Ghatwai, Antonino Montalbano, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Visualized Experiments : Jove|February 9, 2019
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index EquationMeriem Bahri, Julien Fleurence, Sébastien Faraj, et al.
Journal of Immunology Research|February 4, 2017
Targeting <i>O</i>-Acetyl-GD2 Ganglioside for Cancer ImmunotherapyJulien Fleurence, Sophie Fougeray, Meriem Bahri, et al.
Oncoimmunology|June 5, 2013
Inhibition of tumor angiogenesis by globotriaosylceramide immunotargetingStéphane Birklé, Ariane Desselle, Tanguy Chaumette, et al.
Plos One|November 29, 2012
Anti-Gb3 monoclonal antibody inhibits angiogenesis and tumor developmentAriane Desselle, Tanguy Chaumette, Marie-Hélène Gaugler, et al.
Oncotarget|May 14, 2016
Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 gangliosideJulien Fleurence, Denis Cochonneau, Sophie Fougeray, et al.
Cancer Immunology Research|January 19, 2020
Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular CarcinomaSai Arun Batra, Purva Rathi, Linjie Guo, et al.
International Journal of Cancer|June 27, 2019
Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 gangliosideJulien Fleurence, Meriem Bahri, Sophie Fougeray, et al.
Research Square|April 22, 2024
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancersDavid Steffin, Nisha Ghatwai, Antonino Montalbano, et al.
Nature|November 28, 2024
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancersDavid Steffin, Nisha Ghatwai, Antonino Montalbano, et al.
Pageof 1